Live Breaking News & Updates on Pharmacy benefit manager reform
Stay updated with breaking news from Pharmacy benefit manager reform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The first six months of the 118th Congress have been an active stretch for the House and Senate committees with jurisdiction over health care issues. Legislative activity has spanned the health...
Congress is taking a closer look at business practices in the health care sector and considering bipartisan reforms in light of increasing consolidation and its perceived affects on...
Both the House and Senate are considering multiple bipartisan bills concerning pharmacy benefit managers (PBMs), meaning action is likely this year. However, the timeline and path...
This Week in Washington: Debt Ceiling Continues to Loom Over the Capitol; DEA Extends COVID-19 Controlled Medications Prescribing Telehealth Flexibilities...
U.S. Sen. Tim Kaine celebrates committee passage of bipartisan legislation to lower drug costs wmdt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wmdt.com Daily Mail and Mail on Sunday newspapers.
Last week, the Senate Health, Education, Labor, and Pensions (HELP) Committee held two important meetings regarding PBM regulation. One on May 10 entitled, “The Need to Make Insulin Affordable to All Americans,” examined incentives to lower prescription drug prices, including but not limited to prices for insulin. The hearing featured testimony from three major pharmaceutical manufacturers and three major pharmacy benefit managers (PBMs).
The U.S. House of Representatives and U.S. Senate are both in session for what is shaping up to be a busy healthcare week. The House Energy and Commerce Health Subcommittee scheduled...
Republican 2022 midterms underperformance is not expected to dampen Congressional Pharmacy Benefit Manager PBM reform. Issue remains at forefront of healthcare pricing debate. No longer seen as Republican-driven effort due to Inflation Reduction Act IRA drug pricing reforms.